CY1120861T1 - Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη διαβητη τυπου 1 - Google Patents

Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη διαβητη τυπου 1

Info

Publication number
CY1120861T1
CY1120861T1 CY181100931T CY181100931T CY1120861T1 CY 1120861 T1 CY1120861 T1 CY 1120861T1 CY 181100931 T CY181100931 T CY 181100931T CY 181100931 T CY181100931 T CY 181100931T CY 1120861 T1 CY1120861 T1 CY 1120861T1
Authority
CY
Cyprus
Prior art keywords
methods
compositions
treatment
diabetes type
administering
Prior art date
Application number
CY181100931T
Other languages
English (en)
Inventor
Bart O Roep
William H Robinson
Paul Utz
Hideki Garren
Lawrence Steinman
Original Assignee
Tolerion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolerion filed Critical Tolerion
Publication of CY1120861T1 publication Critical patent/CY1120861T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει συνθέσεις και μεθόδους για θεραπευτική αγωγή ινσουλινοεξαρτώμενου σακχαρώδη διαβήτη σε υποκείμενο που περιλαμβάνει χορήγηση αυτοφορέα που κωδικοποιεί και εκφράζει ανθρώπινη προϊνσουλίνη.
CY181100931T 2013-05-02 2018-09-06 Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη διαβητη τυπου 1 CY1120861T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818671P 2013-05-02 2013-05-02
PCT/US2014/036394 WO2014179586A1 (en) 2013-05-02 2014-05-01 Compositions and methods for treatment of type 1 diabetes

Publications (1)

Publication Number Publication Date
CY1120861T1 true CY1120861T1 (el) 2019-12-11

Family

ID=51843952

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100931T CY1120861T1 (el) 2013-05-02 2018-09-06 Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη διαβητη τυπου 1

Country Status (14)

Country Link
US (2) US20160068585A1 (el)
EP (1) EP2992094B1 (el)
JP (2) JP2016518844A (el)
CN (1) CN105408478A (el)
CY (1) CY1120861T1 (el)
DK (1) DK2992094T3 (el)
ES (1) ES2687189T3 (el)
HR (1) HRP20181445T1 (el)
HU (1) HUE040421T2 (el)
LT (1) LT2992094T (el)
PL (1) PL2992094T3 (el)
PT (1) PT2992094T (el)
SI (1) SI2992094T1 (el)
WO (1) WO2014179586A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364261A1 (en) * 2020-09-21 2023-11-16 Sri International Targeted antigen delivery system and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002045735A2 (en) * 2000-12-08 2002-06-13 University Technologies International, Inc. Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus
WO2010080976A1 (en) * 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
US20180092991A1 (en) * 2009-06-05 2018-04-05 Bayhill Therapeutics, Inc. Compositions and methods for treatment of insulin-dependent diabetes mellitus
WO2012015903A1 (en) * 2010-07-27 2012-02-02 Bayhill Therapeutics, Inc. Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients

Also Published As

Publication number Publication date
JP2016518844A (ja) 2016-06-30
PT2992094T (pt) 2018-10-18
CN105408478A (zh) 2016-03-16
DK2992094T3 (en) 2018-09-03
EP2992094B1 (en) 2018-06-20
JP2019080574A (ja) 2019-05-30
EP2992094A4 (en) 2016-12-28
LT2992094T (lt) 2018-11-12
PL2992094T3 (pl) 2019-03-29
HRP20181445T1 (hr) 2018-11-16
SI2992094T1 (sl) 2018-12-31
US20160068585A1 (en) 2016-03-10
ES2687189T3 (es) 2018-10-24
EP2992094A1 (en) 2016-03-09
US20190315827A1 (en) 2019-10-17
WO2014179586A1 (en) 2014-11-06
HUE040421T2 (hu) 2019-03-28

Similar Documents

Publication Publication Date Title
CY1121153T1 (el) Παραγωγα εξενδινης-4 ως διπλοι glp1/gιp- ή τριγωνικοι αγωνιστες glp1/gιp/γλυκαγονης
CY1119987T1 (el) Παραγωγα εξενδινης-4 ως διττοι αγωνιστες glp1/γλυκαγονης
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
CY1122671T1 (el) Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
UA118558C2 (uk) Пептидна сполука
CY1121736T1 (el) Άλατα aramchol
EA201890641A3 (ru) Стимуляторы sgc
BR112018067731A2 (pt) coagonistas de glucagon e glp-1 para o tratamento de obesidade
EA201590058A1 (ru) Аналоги глюкагона
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015015249A (es) Peptidos terapeuticos.
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
EA201992562A1 (ru) Пептиды для лечения сахарного диабета
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида